GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » EPS (Diluted)

Immunotech Biopharm (HKSE:06978) EPS (Diluted) : HK$-0.71 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm EPS (Diluted)?

Immunotech Biopharm's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.46. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.71.

Immunotech Biopharm's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.71.

Immunotech Biopharm's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.29. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.52.

During the past 3 years, the average EPS without NRIGrowth Rate was 22.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -40.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Immunotech Biopharm's highest 3-Year average EPS without NRI Growth Rate was 22.80% per year. The lowest was -115.70% per year. And the median was -36.80% per year.


Immunotech Biopharm EPS (Diluted) Historical Data

The historical data trend for Immunotech Biopharm's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm EPS (Diluted) Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -0.24 -1.17 -0.85 -0.69 -0.71

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.49 -0.32 -0.39 -0.25 -0.46

Competitive Comparison of Immunotech Biopharm's EPS (Diluted)

For the Biotechnology subindustry, Immunotech Biopharm's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's PE Ratio distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's PE Ratio falls into.



Immunotech Biopharm EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Immunotech Biopharm's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-366.218-0)/514.584
=-0.71

Immunotech Biopharm's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-237.027-0)/514.584
=-0.46

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunotech Biopharm  (HKSE:06978) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Immunotech Biopharm EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm (HKSE:06978) Business Description

Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Tian Jin He Yue Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Wu Naifeng 2501 Other
Yan Kaijing 2501 Other
Yan Xijun 2501 Other
Tian Shi Li Kong Gu Ji Tuan You Xian Gong Si 2501 Other
Tian Shi Li Yi Yao Ji Tuan Gu Fen You Xian Gong Si 2501 Other
Tian Jin Di Zhi Tou Zi Guan Li You Xian Gong Si 2501 Other
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Li Yunhui 2501 Other
Tian Jin Hong Xun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Kang Shun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shan Zhen Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shun Qi Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other

Immunotech Biopharm (HKSE:06978) Headlines

No Headlines